Miami, FL – November 2024 – Global Stem Cells Group (GSCG), a recognized leader in
regenerative medicine and cellular therapies, is pleased to announce the upcoming launch of a
new clinic, set to open on November 23, 2024, in Dubai. This strategic initiative represents a
significant expansion of GSCG’s global footprint, as it seeks to offer advanced regenerative
solutions to new and vital markets.

The new clinic, located at the Hyatt Hotel in Jumeirah, is poised to become a hub for cutting-
edge regenerative treatments. The clinic aims to provide a comprehensive range of therapies,
including stem cell treatments, exosome applications, natural killer (NK) cell therapies, aesthetic
procedures, and interventions focused on promoting longevity. GSCG aspires to enhance
patient access to these innovative treatments across the region.

ISSCA to Host Conference in Dubai on November 22 and 23 Using Global Stem Cells Group’s Facilities

The International Society for Stem Cell Application (ISSCA), the educational division of Global
Stem Cells Group, will host a two-day conference as part of its 2.0 series, featuring the latest
advancements in regenerative medicine. Scheduled for November 22 and 23, this event will
include theoretical sessions on the first day at the Le Méridien Dubai Hotel & Conference
Centre, followed by practical hands-on demonstrations at the new Global Stem Cells Group
clinic on the second day. The hands-on portion, taking place on November 23, will provide
attendees with the opportunity to apply their knowledge directly in a clinical setting, under the
guidance of top experts in regenerative medicine.

The conference will feature top speakers in the field, who will share their insights and
advancements in various areas of regenerative medicine. Topics covered at the conference
include NK Cells, allogeneic PRP, human placenta, nanorevive, progenicell, peptides, CAR-T
cells, 3D bioprinting, biohacking, Wharton’s jelly, young donor plasma, and exosomes MSC.
This comprehensive agenda is designed to provide in-depth knowledge on cutting-edge
therapies such as peptides, NK cells, donor-derived stem cells, exosomes, and other advanced
treatment modalities. ISSCA’s 2.0 series seeks to equip medical professionals with updated
knowledge and skills in the most recent developments in regenerative therapies.

“We hope that this new clinic in Dubai will establish itself as a center of excellence, not only for
treatment but also for continuous education,” said Benito Novas, founder and CEO of Global
Stem Cells Group. “We believe this initiative will empower both doctors and patients by
providing access to innovative regenerative solutions. We expect it to be a meaningful milestone
in expanding our mission to deliver transformative medical therapies globally.”

A Distribution Hub for Cellgenic Products in the Middle East

The Dubai clinic is expected to serve as a key distribution center for Cellgenic products,
including the registered lyophilized exosome product. The goal is to enable efficient local and
international distribution, facilitating access to advanced regenerative products throughout the
region.

The Growing Global Demand for Regenerative Medicine

The regenerative medicine sector continues to grow, driven by increasing demand for
treatments that support healing, promote longevity, and improve overall health. With over 15
years of experience, Global Stem Cells Group aims to contribute meaningfully to this evolving
field by offering comprehensive solutions designed to address complex conditions and enhance
patient quality of life.

The Dubai clinic is expected to offer an extensive range of therapies, including:
● Mesenchymal Stem Cell (MSC) therapies, believed to promote tissue repair and overall
health.
● Exosome therapies, anticipated to support aesthetic enhancements and orthopedic
recovery.
● Natural Killer (NK) cell therapies, which aim to enhance immune system function.
● Anti-aging and longevity treatments, combining cellular therapies with therapeutic
peptides.
● Platelet-Rich Plasma (PRP) injections, expected to accelerate healing and rejuvenation.
● Specialized therapeutic peptides, aimed at addressing specific health conditions.

Dubai as a Promising Destination for Medical Tourism

Dubai’s international reputation as a premier destination positions it well to attract patients
seeking advanced regenerative treatments. GSCG anticipates that the new clinic will draw
interest from medical tourists worldwide, offering tailored treatment plans for conditions such as
autoimmune disorders, orthopedic injuries, and skin rejuvenation. The combination of innovative
medical solutions and a patient-centric approach is expected to make the Dubai clinic a vital
part of the city’s emerging status as a hub for advanced healthcare.
About Global Stem Cells Group
Founded by Benito Novas, Global Stem Cells Group seeks to advance the field of regenerative
medicine globally. With a robust presence across continents, the organization provides both
treatments and educational programs aimed at empowering doctors, researchers, and patients.
Through ISSCA, GSCG conducts specialized training, certification, and hands-on workshops
designed to promote best practices in the application of cellular therapies.
For more information about the Dubai clinic opening, ISSCA training event, or Global Stem Cells
Group, please visit the Global Stem Cells Group website.

Global Stem Cells Group is a publicly traded company operating under the symbol RMTG.
https://finance.yahoo.com/quote/RMTG/

To learn more about Global Stem Cells Group, Inc.’s companies, visit our website
www.stemcellsgroup.com or call +1 305 560 5331.

Safe Harbor Statement: Statements in this news release may be “forward-looking statements”.
Forward-looking statements include, but are not limited to, statements that express our
intentions, beliefs, expectations, strategies, predictions, or any other information relating to our
future activities or other future events or conditions. These statements are based on current
expectations, estimates, and projections about our business based partly on assumptions made
by management. These statements are not guarantees of future performance and involve risks,
uncertainties, and assumptions that are difficult to predict. Therefore, actual outcomes and
results may and are likely to differ materially from what is expressed or forecasted in forward-
looking statements due to numerous factors. Any forward-looking statements speak only as of
the date of this news release, and The Global Stem Cells Group undertakes no obligation to
update any forward-looking statement to reflect events or circumstances after the date of this
news release. This press release does not constitute a public offer of any securities for sale.
Any securities offered privately will not be or have not been registered under the Act and may
not be offered or sold in the United States absent registration or an applicable exemption from
registration requirements.

Miami, Florida – The International Society for Stem Cell Application (ISSCA), a division of the Global Stem Cells Group (GSCG), is excited to announce its upcoming international conference on Regenerative Medicine and Cellular Therapies, set to take place in Buenos Aires, Argentina, on October 25 and 26, 2024. This event promises to be a pivotal gathering for medical professionals from around the world, offering a full day of expert-led presentations followed by an immersive day of hands-on training.

A Hub of Innovation and Knowledge in Regenerative Medicine

Regenerative medicine is rapidly transforming the healthcare landscape, offering revolutionary treatments that can repair or replace damaged tissues and cells, opening new avenues for both doctors and patients. This conference provides an exceptional platform for global experts to share the latest advancements, breakthrough research, and clinical applications in regenerative medicine and cellular therapies. For medical professionals, attending this event will enable them to expand their knowledge in regenerative medicine to enhance their practice, and improve patient outcomes.

Expanding the Reach of Regenerative Medicine

Events like ISSCA’s Buenos Aires conference play a crucial role in the global expansion of regenerative medicine. For doctors, this is an opportunity to learn about cutting-edge treatments, innovative technologies, and the most recent regulatory frameworks. With practical insights into therapies like stem cell treatments, exosomes, and peptide-based interventions, physicians can bring these advancements directly into their practices, benefiting their patients with pioneering care.

For patients, the expansion of regenerative medicine means improved access to therapies that can treat a wide range of conditions— from chronic diseases to acute injuries, and even aesthetic applications. By bridging the gap between research and clinical practice, events like this accelerate the adoption of novel treatments that enhance both the quality of care and the possibilities for recovery.

“We have been conducting conferences in this incredible country for 15 years,” said Benito Novas, Vice President of ISSCA. “Buenos Aires has always welcomed us with open arms and great warmth. I love this city, and Argentina remains one of our most important partners in advancing the science of regenerative medicine.”

Key Topics to Be Covered at the Conference:

• Peptides: The Next Frontier in Regenerative Therapies
  Explore the burgeoning field of peptide-based therapies and their application in various medical specialties, offering new options for patient treatment and recovery.
• Exosomes: The Future of Cellular Medicine
  Discover how exosomes, tiny extracellular vesicles, are revolutionizing medicine, especially in facial rejuvenation, wound healing, and orthopedic therapies.
• Tissue Engineering: A New Era of Medical Innovation
  Attendees will learn how tissue engineering is shaping the future of regenerative medicine, creating new possibilities for tissue regeneration and clinical applications.
• Autologous Mesenchymal Stem Cell Applications
  A deep dive into the use of autologous mesenchymal stem cells in treating neurological disorders, spinal injuries, and chronic illnesses, with real-world examples of successful outcomes.
• Regenerative Therapies in Sports Medicine
  Learn about cutting-edge regenerative treatments in sports medicine, including stem cell and exosome therapies that accelerate recovery and enhance performance.
• Venous Ulcer Treatment through Regenerative Medicine
  Attendees will explore advanced treatments for chronic wounds, focusing on venous ulcers and how regenerative therapies offer improved healing rates.
• Advances in Genital Reconstructive Surgery
  This session will focus on the innovative use of regenerative therapies in genital reconstructive surgery, improving patient outcomes in gynecological health.
• Hands-On Training: Practical Applications of Regenerative Medicine
  Engage in live demonstrations and hands-on training in key areas such as adipose tissue processing, bone marrow extraction, exosome-based therapies, and fibroblast implants.

The Role of Events in Driving Global Change

ISSCA’s annual conferences are more than just gatherings of experts; we believe they are pivotal moments that drive the global expansion of regenerative medicine. By fostering a community of innovation, collaboration, and knowledge-sharing, ISSCA hopes to support the widespread adoption of new technologies and treatments, ultimately benefiting patients.

“Events like our Buenos Aires conference help build a network of professionals committed to advancing patient care through regenerative medicine,” added Novas. “Our aim is to provide medical practitioners with the knowledge and tools necessary to adopt innovative therapies.”

Join Us in Buenos Aires

ISSCA’s International Conference on Regenerative Medicine and Cellular Therapies is expected to be an invaluable experience for healthcare professionals looking to stay informed on the latest developments in medical science. The conference will conclude with a gala dinner and certificate presentation for attendees.

For more information and to register, visit: www.issca.com

About ISSCA

The International Society for Stem Cell Application (ISSCA) is a leading organization in the field of regenerative medicine. It is dedicated to advancing the science and practice of stem cell therapy and regenerative medicine through education, certification, research, and training. ISSCA provides certification training in cities worldwide, recognizing the importance of standards and certifications in regenerative medicine as a medical specialty.

ISSCA’s mission is to promote the benefits of stem cell medicine to patients globally, ensure the quality and uniformity of regenerative medicine practices, and establish itself as a global leader in the certification and education of medical professionals in this field. The organization is a distinguished division of the Global Stem Cells Group (GSCG) and has over 15 years of experience in the industry, making significant contributions to the advancement and dissemination of regenerative medicine knowledge and practices.

About Global Stem Cells Group

Global Stem Cells Group is a leading provider of regenerative medicine solutions, dedicated to advancing healthcare through innovative therapies. With a global presence and a multidisciplinary team of experts, the organization strives to harness the potential of stem cells and regenerative medicine to improve patient outcomes across various medical fields. Through its extensive network of clinics, research facilities, and training centers, Global Stem Cells Group is committed to pushing the boundaries of regenerative medicine and making a positive impact on global healthcare.

Global Stem Cells Group is a publicly traded company operating under the symbol MSSV. https://finance.yahoo.com/quote/mssv/

To learn more about Global Stem Cells Group, Inc.’s companies visit our website www.stemcellsgroup.com or call +1 305 560 5331

Safe Harbor Statement: Statements in this news release may be “forward-looking statements”. Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions, or any other information relating to our future activities or other future events or conditions. These statements are based on current expectations, estimates, and projections about our business based partly on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties, and assumptions that are difficult to predict. Therefore, actual outcomes and results may and are likely to differ materially from what is expressed or forecasted in forward-looking statements due to numerous factors. Any forward-looking statements speak only as of the date of this news release, and The Global Stem Cells Group undertakes no obligation to update any forward-looking statement to reflect events or circumstances after the date of this news release. This press release does not constitute a public offer of any securities for sale. Any securities offered privately will not be or have not been registered under the Act and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.

Miami, FL – September 2024 –The International Society for Stem Cell Application (ISSCA), a division of Global Stem Cells Group (GSCG), is pleased to announce the launch of its new training series, Mastering Next-Generation Cellular Therapies and Regenerative Medicine 2.0. This training will be held in two prominent locations: Cancun, Mexico, on October 4th and 5th, 2024, followed by Dubai, UAE, on November 22nd and 23rd, 2024.

Building on ISSCA’s long-standing commitment to advancing regenerative medicine, this training series aims to provide participants with the most up-to-date knowledge and techniques in the field. This 2.0 iteration of ISSCA’s training is designed to focus on the next generation of cellular therapies, with the goal of equipping healthcare professionals with the tools necessary to explore and incorporate these innovations into their practices. The agenda for this training is structured to present the most recent advancements, offering attendees both theoretical knowledge and practical experience in cutting-edge therapies.

Key Topics to be Covered:

• NK Cells for Anti-Aging and Immune Support: This session is expected to provide insights into the emerging applications of NK cells in enhancing immune responses and supporting anti-aging treatments.
• Progenicell and Nanorevive Technologies: These innovative technologies will be introduced, highlighting their potential roles in tissue repair and cellular recovery.
• Peptides for Longevity and Tissue Healing: Participants will explore the latest applications of peptides, which may contribute to improved tissue regeneration, reduced inflammation, and overall health optimization.
• Wharton’s Jelly in Regenerative Medicine: Attendees will learn about the promising uses of Wharton’s Jelly in regenerative medicine, particularly in addressing degenerative conditions.
• Biohacking for Medical Optimization: This session will delve into biohacking principles and their potential integration into modern clinical practices for enhanced patient outcomes.

The Importance of Staying at the Forefront of Cellular Therapies

In light of the rapidly evolving landscape of regenerative medicine, it is increasingly important for medical professionals to remain at the forefront of technological advancements. This training seeks to support clinicians in staying updated with the latest developments in the field, which may have a significant impact on improving patient outcomes. By mastering next-generation therapies such as NK cells, peptides, and Wharton’s Jelly applications, we believe attendees will be better positioned to explore innovative treatment options in their clinical practices.

ISSCA’s Mission and Impact

ISSCA is dedicated to advancing the science and application of cellular therapies and regenerative medicine. The organization continuously strives to bring the most current developments to healthcare professionals, thereby fostering the adoption of advanced techniques that may improve patient care. Through ongoing research, ISSCA endeavors to develop new tools, methodologies, and educational resources that will empower doctors to enhance their medical practices.

The impact of ISSCA’s work extends across the global medical community, offering practitioners access to the most up-to-date therapies and enabling them to stay ahead of the curve in this rapidly changing field. By facilitating this comprehensive training, ISSCA aims to contribute to the ongoing professional development of doctors and researchers, ensuring that they are equipped with the latest knowledge and techniques in regenerative medicine.

Event Highlights:

• Comprehensive coverage of topics including NK Cells, Peptides, Progenicell, and other emerging therapies;
• Hands-on training sessions, designed to offer practical experience in next-generation regenerative treatments;
• Two international training opportunities: Cancun, Mexico, and Dubai, UAE;
• ISSCA’s latest research-driven content, developed to support practitioners in staying informed of the latest advancements in the field;
• Certification upon completion, recognizing expertise in cellular therapies and regenerative medicine; and
• Networking opportunities with global leaders and experts in the field.

Event Details:

• Cancun, Mexico: October 4 & 5, 2024
• Dubai, UAE: November 22 & 23, 2024
• Contact: For further information and registration, please visit www.issca.com or contact info@stemcellsgroup.com | +1 (754) 799 4946

ISSCA anticipates that these training events will provide a valuable opportunity for healthcare professionals, clinicians, and researchers to gain essential insights into the future of regenerative medicine. Early registration is encouraged due to limited capacity.

About ISSCA

The International Society for Stem Cell Application (ISSCA) is a leading organization in the field of regenerative medicine. It is dedicated to advancing the science and practice of stem cell therapy and regenerative medicine through education, certification, research, and training. ISSCA provides certification training in cities worldwide, recognizing the importance of standards and certifications in regenerative medicine as a medical specialty.

ISSCA’s mission is to promote the benefits of stem cell medicine to patients globally, ensure the quality and uniformity of regenerative medicine practices, and establish itself as a global leader in the certification and education of medical professionals in this field. The organization is a distinguished division of the Global Stem Cells Group (GSCG) and has over 15 years of experience in the industry, making significant contributions to the advancement and dissemination of regenerative medicine knowledge and practices.

About Global Stem Cells Group

Global Stem Cells Group is a leading provider of regenerative medicine solutions, dedicated to advancing healthcare through innovative therapies. With a global presence and a multidisciplinary team of experts, the organization strives to harness the potential of stem cells and regenerative medicine to improve patient outcomes across various medical fields. Through its extensive network of clinics, research facilities, and training centers, Global Stem Cells Group is committed to pushing the boundaries of regenerative medicine and making a positive impact on global healthcare.

Global Stem Cells Group is a publicly traded company operating under the symbol MSSV. https://finance.yahoo.com/quote/mssv/

To learn more about Global Stem Cells Group, Inc.’s companies visit our website www.stemcellsgroup.com or call +1 305 560 5331

Safe Harbor Statement: Statements in this news release may be “forward-looking statements”. Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions, or any other information relating to our future activities or other future events or conditions. These statements are based on current expectations, estimates, and projections about our business based partly on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties, and assumptions that are difficult to predict. Therefore, actual outcomes and results may and are likely to differ materially from what is expressed or forecasted in forward-looking statements due to numerous factors. Any forward-looking statements speak only as of the date of this news release, and The Global Stem Cells Group undertakes no obligation to update any forward-looking statement to reflect events or circumstances after the date of this news release. This press release does not constitute a public offer of any securities for sale. Any securities offered privately will not be or have not been registered under the Act and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.

Miami, Florida – The International Society for Stem Cell Application (ISSCA) is pleased to announce that an advanced training course on Functional Regenerative Medicine and Obesity will be held on October 13 and 14, 2024, at the Cellular Hope Institute in Cancun, Mexico. This two-day, immersive course aims to introduce healthcare professionals to innovative and integrative approaches to managing obesity, combining functional medicine and regenerative therapies.

Tackling a Global Health Crisis with New Approaches

With more than 650 million adults worldwide classified as obese, according to the World Health Organization (WHO), obesity has become one of the most urgent health challenges today. It not only increases the risk of chronic conditions such as cardiovascular disease and diabetes but also disrupts various bodily systems, contributing to metabolic dysfunction and inflammation. ISSCA’s upcoming training is designed to explore alternatives that go beyond conventional treatments, focusing on the root causes of obesity and offering patient-centered solutions.

Open to All Medical Specialties

The course is designed to be accessible to healthcare professionals across all specialties, as obesity can impact the function of multiple bodily systems. Whether practitioners are focused on primary care, regenerative medicine, or other fields, ISSCA believes that this training will provide valuable insights into how obesity-related issues can be addressed through functional and regenerative techniques.

Course Highlights: Topics and Training

• Non-Endoscopic Gastric Balloon Placement
  Led by Dr. Mario Ojeda, this session will introduce non-invasive gastric balloon techniques that offer an alternative for managing obesity. Participants will explore patient assessment, technique, post-procedure care, and the importance of psychological and nutritional support. Live demonstrations and case studies will provide participants with practical, real-world knowledge.
• Regenerative Therapies for Obesity and Inflammation
  Dr. Silvina Pastrana will discuss how regenerative medicine may be used to support weight management by addressing underlying inflammation, a common contributor to obesity. Attendees will learn about the potential use of exosome-based treatments and peptide therapies such as semaglutide, tirzepatide, ipamorelin, and MOTS-C, which are emerging as alternatives in the field of metabolic regulation.
• IV Therapy and Nutritional Supplementation
  Attendees will also explore IV therapies that may enhance metabolic function and support weight management efforts. Dr. Pastrana will discuss detox drips, metabolic boosters, and antioxidants, and how these therapies could complement other treatments for patients struggling with obesity.
• Functional Medicine and Gut Health
  Dr. Andrea Marquez will focus on functional medicine’s role in treating obesity, emphasizing gut health and its connection to weight management. Topics will include insulin resistance, leaky gut syndrome, and common nutritional deficiencies. Attendees will learn how addressing these root causes could potentially lead to more effective and sustainable weight management strategies for patients.

A Holistic Approach to Patient Wellness

This course is expected to emphasize the importance of treating obesity through a comprehensive approach that addresses both metabolic function and overall patient wellness. ISSCA hopes that by incorporating regenerative medicine and functional treatments, healthcare providers can offer patients alternative, integrative solutions that target the root causes of obesity rather than relying on conventional methods alone.

Hands-On Experience and Certification

Participants will have the opportunity to engage in hands-on training sessions, including live demonstrations of non-invasive gastric balloon placement, IV therapies, and peptide treatments. At the conclusion of the course, attendees will receive a digital certificate of completion, along with access to recorded class videos and additional supporting documentation for ongoing reference.

A Step Toward New Solutions in Obesity Management

As obesity continues to rise globally, ISSCA aims to provide healthcare professionals with new strategies and alternatives that could help address this growing crisis. The Functional Regenerative Medicine and Obesity course is a step toward integrating holistic, patient-centered treatments into clinical practice.

About ISSCA

The International Society for Stem Cell Application (ISSCA) is a leading organization in the field of regenerative medicine. It is dedicated to advancing the science and practice of stem cell therapy and regenerative medicine through education, certification, research, and training. ISSCA provides certification training in cities worldwide, recognizing the importance of standards and certifications in regenerative medicine as a medical specialty.

ISSCA’s mission is to promote the benefits of stem cell medicine to patients globally, ensure the quality and uniformity of regenerative medicine practices, and establish itself as a global leader in the certification and education of medical professionals in this field. The organization is a distinguished division of the Global Stem Cells Group (GSCG) and has over 15 years of experience in the industry, making significant contributions to the advancement and dissemination of regenerative medicine knowledge and practices.

About Global Stem Cells Group

Global Stem Cells Group is a leading provider of regenerative medicine solutions, dedicated to advancing healthcare through innovative therapies. With a global presence and a multidisciplinary team of experts, the organization strives to harness the potential of stem cells and regenerative medicine to improve patient outcomes across various medical fields. Through its extensive network of clinics, research facilities, and training centers, Global Stem Cells Group is committed to pushing the boundaries of regenerative medicine and making a positive impact on global healthcare.

Global Stem Cells Group is a publicly traded company operating under the symbol MSSV. https://finance.yahoo.com/quote/mssv/

To learn more about Global Stem Cells Group, Inc.’s companies visit our website www.stemcellsgroup.com or call +1 305 560 5331

Safe Harbor Statement: Statements in this news release may be “forward-looking statements”. Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions, or any other information relating to our future activities or other future events or conditions. These statements are based on current expectations, estimates, and projections about our business based partly on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties, and assumptions that are difficult to predict. Therefore, actual outcomes and results may and are likely to differ materially from what is expressed or forecasted in forward-looking statements due to numerous factors. Any forward-looking statements speak only as of the date of this news release, and The Global Stem Cells Group undertakes no obligation to update any forward-looking statement to reflect events or circumstances after the date of this news release. This press release does not constitute a public offer of any securities for sale. Any securities offered privately will not be or have not been registered under the Act and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.

Miami, FL – August 2024 – Cellgenic, a division of Global Stem Cells Group and a global leader in regenerative medicine, is pleased to announce its sponsorship of three major medical events in Peru this September, where the company will prominently feature its advanced exosome and peptide products. This sponsorship underscores Cellgenic’s commitment to expanding its presence in the rapidly growing Latin American market for regenerative medicine.

Event Details:

• International Regenerative Medicine Conference by ISSCA – September 6-7, 2024: Taking place at the prestigious Hilton Hotel, this event, hosted by the International Society for Stem Cell Application (ISSCA), will gather leading experts from around the world to discuss the latest advancements in stem cell research and regenerative therapies.
• AMDAL 2024 – September 14-15, 2024: Held at the Sol de Oro Hotel in Miraflores, AMDAL 2024 will focus on the latest innovations in dermatology and laser treatments. This event will bring together professionals from across the medical and aesthetic fields to explore cutting-edge technologies and practices.
• MDE24 International Congress of Medicine and Aesthetic Dermatology – September 20-21, 2024: This event, set to take place at the ESAN Convention Center, will highlight groundbreaking developments in aesthetic dermatology and medical treatments, attracting participants from across the globe.

These events will feature a diverse lineup of international and local speakers, as well as participating doctors from Peru and neighboring regions. As a sponsor, Cellgenic will have a unique opportunity to introduce its pioneering exosome technology to the attending medical professionals, demonstrating why exosomes represent a promising and expanding market in Latin America.

“Cellgenic is honored to participate in these prestigious events, where we will showcase our latest innovations in regenerative medicine,” said Benito Novas, Founder of Global Stem Cells Group. “We are particularly excited to introduce our exosome products to a new audience in this region. Additionally, we are leveraging these platforms to officially launch our new line of peptides, which we believe could offer significant benefits to medical professionals and patients alike.”

Exosomes, derived from mesenchymal stem cells, have been increasingly recognized for their potential in enhancing regenerative processes, offering new avenues for treatment in areas such as aesthetic medicine, orthopedics, and chronic conditions. The Latin American market, with its growing focus on advanced medical therapies, might be poised for significant growth in the adoption of exosome-based treatments.

Sarah Barroso, Director of Cellgenic, emphasized the strategic importance for the company’s presence in Peru. “Doctors in Peru have consistently shown a strong interest in our exosome products, and our participation in these conferences represents a crucial opportunity for us to expand our footprint in this promising market,” Barroso stated. “We are confident that our exosomes and peptides will meet the evolving needs of healthcare professionals in the region, providing them with innovative tools to improve patient outcomes.”

About Cellgenic

As a division of Global Stem Cells Group, Cellgenic is driven by a commitment to lead the way in regenerative medicine. By continuously expanding its product offerings, including exosomes and peptides, and staying at the forefront of scientific research, Cellgenic aims to meet the increasing demand for advanced, effective, and safe therapies in Latin America and beyond. The potential of exosomes and peptides to revolutionize patient care might position Cellgenic as a key player in this rapidly evolving landscape.

About Global Stem Cells Group

Global Stem Cells Group is a leading provider of regenerative medicine solutions, dedicated to advancing healthcare through innovative therapies. With a global presence and a multidisciplinary team of experts, the organization strives to harness the potential of stem cells and regenerative medicine to improve patient outcomes across various medical fields. Through its extensive network of clinics, research facilities, and training centers, Global Stem Cells Group is committed to pushing the boundaries of regenerative medicine and making a positive impact on global healthcare.

Global Stem Cells Group is a publicly traded company operating under the symbol MSSV. https://finance.yahoo.com/quote/mssv/

To learn more about Global Stem Cells Group, Inc.’s companies visit our website www.stemcellsgroup.com or call +1 305 560 5331

Safe Harbor Statement: Statements in this news release may be “forward-looking statements”. Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions, or any other information relating to our future activities or other future events or conditions. These statements are based on current expectations, estimates, and projections about our business based partly on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties, and assumptions that are difficult to predict. Therefore, actual outcomes and results may and are likely to differ materially from what is expressed or forecasted in forward-looking statements due to numerous factors. Any forward-looking statements speak only as of the date of this news release, and The Global Stem Cells Group undertakes no obligation to update any forward-looking statement to reflect events or circumstances after the date of this news release. This press release does not constitute a public offer of any securities for sale. Any securities offered privately will not be or have not been registered under the Act and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.

Miami, FL — Global Stem Cells Group (GSCG), a renowned leader in regenerative medicine, proudly announces the launch of its innovative Cellgenic peptide line. Cellgenic, the division of GSCG that promotes and distributes innovative products and equipment for physicians in the field of regenerative medicine, introduces this new line of peptides, once again solidifying its mission to provide physicians with cutting-edge solutions to improve patient care.

Peptides in the Field of Regenerative Medicine

Peptides play a crucial role in the field of regenerative medicine by promoting healing, reducing inflammation, and enhancing cellular function. They serve as signaling molecules that can influence various biological processes, making them an alternative in the treatment of injuries, chronic conditions, and age-related degeneration. By integrating peptides into their product offerings, Cellgenic intends to provide healthcare professionals with powerful tools to improve patient outcomes and advance the efficacy of regenerative therapies. These peptides, when used in conjunction with other cellular therapies, may significantly enhance the body’s natural ability to repair and regenerate tissue.

Cellgenic new peptide line includes:

Healing and Recovery:

1. BPC157: Known for its potential healing properties, BPC157 may accelerate recovery from injuries and support overall tissue repair. This peptide is derived from a protein found in the stomach and has shown promising effects on the healing of muscles, tendons, and ligaments.
2. TB500: A potent peptide that may enhance muscle recovery and reduce inflammation, TB500 is ideal for athletes and individuals with chronic injuries. It mimics the effects of Thymosin Beta-4, a naturally occurring peptide that plays a crucial role in the body’s healing process by potentially promoting cellular migration and differentiation.

Anti-Aging and Skin Health:

3. GHK-CU: Widely recognized for its potential anti-aging effects, GHK-CU may improve skin appearance and promote wound healing. This copper peptide can stimulate collagen production, enhance skin elasticity, and has shown promise in reducing fine lines and wrinkles, making it a popular choice in cosmetic treatments.
4. Epithalon: Known for its potential ability to regulate the pineal gland, Epithalon may enhance longevity and overall health. It has been studied for its potential to lengthen telomeres, which are protective caps on chromosomes that shorten with age, thereby promoting cellular health and longevity.

Metabolic and Longevity:

5. MOTS-C: This mitochondrial-derived peptide plays a critical role in regulating metabolic functions and promoting longevity. MOTS-C can enhance the body’s ability to convert glucose into energy, which may improve physical performance, increase muscle strength, and support overall metabolic health.
6. SS31: A unique peptide that targets and protects mitochondria, SS31 is instrumental in reducing oxidative stress and improving cellular function. This peptide has shown promise in treating conditions related to mitochondrial dysfunction, such as neurodegenerative diseases and muscle wasting.

Aesthetic and Sexual Health:

7. Melanotan 2: This peptide is widely used for its potential to enhance tanning and improve sexual function. Melanotan 2 stimulates the production of melanin, the pigment responsible for skin color, providing a sunless tanning option and also has aphrodisiac effects.

Growth Hormone and Body Composition:

8. Ipamorelin: As a growth hormone secretagogue, Ipamorelin may be effective for improving body composition and supporting muscle growth. It stimulates the release of growth hormone without affecting cortisol levels, making it a potentially safe and effective option for increasing lean body mass and reducing body fat.
9. Tesamorelin: Known for its ability to increase growth hormone levels, Tesamorelin can be beneficial for improving body composition and metabolic health. It is particularly effective in reducing visceral fat in patients with HIV-associated lipodystrophy and has potential benefits for general weight management.

Weight Management and Diabetes:

10. Semaglutide: A GLP-1 agonist, Semaglutide can be effective for weight loss and managing diabetes. It works by mimicking the hormone GLP-1, which increases insulin secretion, reduces appetite, and slows gastric emptying, thereby promoting weight loss and improving blood sugar control.
11. Tirzepatide: Another GLP-1 agonist, Tirzepatide, is gaining recognition for its significant impact on weight loss and metabolic regulation. It combines the actions of GLP-1 and GIP (glucose-dependent insulinotropic polypeptide), providing enhanced effects on blood sugar control and weight reduction.

Global Stem Cells Group Remains a Leader in the Industry

Global Stem Cells Group’s commitment to innovation and excellence sets it apart from the competition. By continually thinking in ways that others do not, GSCG remains a pioneering force in regenerative medicine. Its approach involves not only developing cutting-edge products but also fostering a collaborative environment with researchers, healthcare providers, and industry experts to ensure the highest standards of quality and efficacy. GSCG’s comprehensive education and training programs further underscore their dedication to advancing the field, ensuring that medical professionals worldwide are well-equipped to utilize the latest regenerative therapies.

Expanding Horizons with Innovative Solutions

Global Stem Cells Group’s growth trajectory is remarkable. With multiple offices around the globe and plans for further expansion, GSCG is dedicated to increasing its outreach and impact in the field of regenerative and restorative medicine. This expansion is not just about opening new offices but also about forging partnerships and collaborations that enhance the company’s ability to deliver state-of-the-art treatments and products. The launch of this new line of peptides is a testament to its unwavering commitment to innovation and excellence, strengthening GSCG’s position as a global leader in regenerative medicine for now and long into the future.

About Cellgenic

Cellgenic is a distinguished brand renowned for its cellular products and kits featuring the latest advancements in regenerative medicine, including Exosomes, Collagenase, PRP, Wharton’s jelly mesenchymal cells, and now peptides. Committed to excellence in research and development, Cellgenic strives to provide healthcare professionals with cutting-edge technologies of the highest quality to enhance patient care and outcomes.

About Global Stem Cells Group

Global Stem Cells Group is a leading provider of regenerative medicine solutions, dedicated to advancing healthcare through innovative therapies. With a global presence and a multidisciplinary team of experts, the organization strives to harness the potential of stem cells and regenerative medicine to improve patient outcomes across various medical fields. Through its extensive network of clinics, research facilities, and training centers, Global Stem Cells Group is committed to pushing the boundaries of regenerative medicine and making a positive impact on global healthcare.

Global Stem Cells Group is a publicly traded company operating under the symbol MSSV. https://finance.yahoo.com/quote/mssv/

To learn more about Global Stem Cells Group, Inc.’s companies visit our website www.stemcellsgroup.com or call +1 305 560 5331

Safe Harbor Statement: Statements in this news release may be “forward-looking statements”. Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions, or any other information relating to our future activities or other future events or conditions. These statements are based on current expectations, estimates, and projections about our business based partly on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties, and assumptions that are difficult to predict. Therefore, actual outcomes and results may and are likely to differ materially from what is expressed or forecasted in forward-looking statements due to numerous factors. Any forward-looking statements speak only as of the date of this news release, and The Global Stem Cells Group undertakes no obligation to update any forward-looking statement to reflect events or circumstances after the date of this news release. This press release does not constitute a public offer of any securities for sale. Any securities offered privately will not be or have not been registered under the Act and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.

Miami, Florida –  Global Stem Cells Group (GSCG) is delighted to announce the grand opening of ReGen Mediterra, a state-of-the-art facility located in the picturesque city of Antalya, Turkey. This new addition to the ReGen Network marks a significant advancement in the field of regenerative medicine and underscores GSCG’s dedication to providing innovative healthcare solutions on a global scale.

Expanding Medical Tourism in Antalya

Antalya, renowned for its breathtaking beaches and stunning landscapes, is one of Turkey’s most sought-after tourist destinations. The city’s allure as a premier hub for medical tourism is further amplified by the establishment of ReGen Mediterra. The facility is poised to attract patients not only from Turkey but from across Europe, seeking cutting-edge anti-aging treatments, advanced stem cell therapies, and non-invasive methods to address various health conditions.

Commitment to Excellence in Regenerative Medicine

“The expansion of the ReGen Clinic network solidifies our position as the largest regenerative medicine network globally. Antalya’s unique position as a top tourist destination makes it an ideal location for medical tourism, offering patients the opportunity to receive world-class treatments while enjoying the region’s natural beauty,” stated Dr. Salih Yildirim, Director of ReGen and President of the International Society for Stem Cell Application (ISSCA).

Stem cell therapy is emerging as an increasingly effective clinical solution for treating conditions that traditional medicine addresses primarily through palliative care and pain management. Patients worldwide are seeking natural regenerative alternatives that offer a reduced risk of potential side effects associated with conventional pharmaceuticals.

Advancing Accessibility and Training

The opening of ReGen Mediterra will facilitate the transition of stem cell therapy and regenerative medicine from elective procedures to accessible treatments for patients throughout Turkey. In addition to providing advanced treatments, the center will serve as a training hub for the International Society for Stem Cell Application (ISSCA), thereby enhancing the knowledge and expertise of healthcare professionals in the region.

Inauguration Ceremony and Conference Highlights

The inauguration ceremony was complemented by a conference, offering regional physicians an opportunity to gain insights into the latest technologies in regenerative medicine and cell therapy. This event underscores GSCG’s commitment to fostering education and collaboration within the medical community.

Future Prospects

As ReGen Mediterra begins its operations, it aims to set new benchmarks in the field of regenerative medicine. The facility will focus on delivering patient-centric care, leveraging the latest advancements in medical technology, and maintaining the highest standards of clinical practice. By doing so, GSCG hopes to make significant contributions to the well-being of patients and the advancement of medical tourism in Antalya.

About Global Stem Cells Group

Global Stem Cells Group is a leading provider of regenerative medicine solutions, dedicated to advancing healthcare through innovative therapies. With a global presence and a multidisciplinary team of experts, the organization strives to harness the potential of stem cells and regenerative medicine to improve patient outcomes across various medical fields. Through its extensive network of clinics, research facilities, and training centers, Global Stem Cells Group is committed to pushing the boundaries of regenerative medicine and making a positive impact on global healthcare.

Global Stem Cells Group is a publicly traded company operating under the symbol MSSV. https://finance.yahoo.com/quote/mssv/

To learn more about Global Stem Cells Group, Inc.’s companies visit our website www.stemcellsgroup.com or call +1 305 560 5331

About ReGen

ReGen is a highly acclaimed Turkish company with clinics in Turkey and several other locations around the world, renowned for its expertise in cutting-edge technologies related to regenerative care. Headquartered in Istanbul, ReGen has gained international recognition for its commitment to excellence and its groundbreaking advancements in regenerative medicine. By partnering with Global Stem Cells Group, ReGen aims to share its advanced techniques and expertise on a global scale, improving access to regenerative care and transforming lives worldwide.

Safe Harbor Statement: Statements in this news release may be “forward-looking statements”. Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions, or any other information relating to our future activities or other future events or conditions. These statements are based on current expectations, estimates, and projections about our business based partly on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties, and assumptions that are difficult to predict. Therefore, actual outcomes and results may and are likely to differ materially from what is expressed or forecasted in forward-looking statements due to numerous factors. Any forward-looking statements speak only as of the date of this news release, and The Global Stem Cells Group undertakes no obligation to update any forward-looking statement to reflect events or circumstances after the date of this news release. This press release does not constitute a public offer of any securities for sale. Any securities offered privately will not be or have not been registered under the Act and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.

Miami, Florida – Global Stem Cells Group (GSCG) is thrilled to announce the grand opening of its latest state-of-the-art Stem Cell Center, located in Jakarta, Indonesia. This new facility, under the membership of ReGen Network, marks the second center in Jakarta and the fourth in Indonesia, reflecting GSCG’s rapid and explosive growth within the regenerative medicine industry.

“Witnessing the rapid and dynamic growth of the regenerative medicine industry, particularly through the pioneering efforts of experts like Dr. Yanti, our medical director in Indonesia, is truly inspiring,” said Benito Novas, a prominent figure in regenerative medicine and the head of Public Relations for GSCG and the International Society for Stem Cell Application (ISSCA).

“The expansion of the ReGen Clinic network solidifies our position as the largest regenerative medicine network globally. Our mission is to implement the best practices in regenerative medicine across various regions, ensuring effective and transformative results,” stated Dr. Salih Yildirim, Director of ReGen and President of ISSCA.

This momentous occasion marks a significant stride forward in the field of regenerative medicine and showcases GSCG’s commitment to providing innovative healthcare solutions worldwide. In a groundbreaking partnership with an esteemed local aesthetic clinic, GSCG introduces its fourth Stem Cell Center in Indonesia, complementing existing facilities in Jakarta, Surabaya, and Bandung. Further underscoring their dedication to advancing medical research, GSCG also anticipates the unveiling of a fifth facility in Bali this year.

ReGen is at the forefront of introducing cutting-edge aesthetic and regenerative treatments, revolutionizing the healthcare landscape. Patients now can have access to the latest treatment options. This partnership underscores Global Stem Cells Group’s vision to make its exceptional services accessible to people around the world.

“We are very proud to be part of ReGen and to contribute to the advancement of regenerative medicine in Indonesia. This new center in Jakarta represents our commitment to providing top-tier medical care and innovative treatments to our patients,” said Dr. Yanti Khusmiran, Medical Director of ReGen Facilities in Indonesia.

While ReGen brings access to clinics, advanced techniques, and expertise, Global Stem Cells Group provides valuable resources as a conglomerate of companies engaged in product manufacturing and comprehensive training through ISSCA. This collaboration has the potential to change the lives of people seeking regenerative care on a global scale.

The newly established center will also serve as a training hub for ISSCA, contributing to the enhancement of knowledge and expertise among healthcare professionals in the region. The opening ceremony was accompanied by onsite training conducted by ISSCA, explaining to all staff standards of practice in regenerative medicine, medical applications of stem cells, and exosomes.

About Global Stem Cells Group

Global Stem Cells Group is a leading provider of regenerative medicine solutions, dedicated to advancing healthcare through innovative therapies. With a global presence and a multidisciplinary team of experts, the organization strives to harness the potential of stem cells and regenerative medicine to improve patient outcomes across various medical fields. Through its extensive network of clinics, research facilities, and training centers, Global Stem Cells Group is committed to pushing the boundaries of regenerative medicine and making a positive impact on global healthcare.

Global Stem Cells Group is a publicly traded company operating under the symbol MSSV. https://finance.yahoo.com/quote/mssv/

To learn more about Global Stem Cells Group, Inc.’s companies visit our website www.stemcellsgroup.com or call +1 305 560 5331

About ReGen

ReGen is a highly acclaimed Turkish company with clinics in Turkey and several other locations around the world, renowned for its expertise in cutting-edge technologies related to regenerative care. Headquartered in Istanbul, ReGen has gained international recognition for its commitment to excellence and its groundbreaking advancements in regenerative medicine. By partnering with Global Stem Cells Group, ReGen aims to share its advanced techniques and expertise on a global scale, improving access to regenerative care and transforming lives worldwide.

About Dr. Yanti Aesthetic Clinic

 Dr. Yanti Aesthetic Clinic is a revered healthcare institution renowned for its state-of-the-art aesthetic and regenerative treatments. With an unwavering dedication to excellence and a forward-thinking approach, Dr. Yanti Aesthetic Clinic is poised to shape the future of regenerative medicine in Indonesia and beyond.

Safe Harbor Statement: Statements in this news release may be “forward-looking statements”. Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions, or any other information relating to our future activities or other future events or conditions. These statements are based on current expectations, estimates, and projections about our business based partly on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties, and assumptions that are difficult to predict. Therefore, actual outcomes and results may and are likely to differ materially from what is expressed or forecasted in forward-looking statements due to numerous factors. Any forward-looking statements speak only as of the date of this news release, and The Global Stem Cells Group undertakes no obligation to update any forward-looking statement to reflect events or circumstances after the date of this news release. This press release does not constitute a public offer of any securities for sale. Any securities offered privately will not be or have not been registered under the Act and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.